All In Biotech

Drug Trial Radar · NCT06063109

A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.

A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Crossover Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of THP-00101 and THP-00102 in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Oct 9, 2023

Primary completion

Nov 9, 2023

Study completion Nov 9, 2023

Sponsor

Lead sponsor
THPharm Corp.Industry
Sponsor type
Industry
First posted
Oct 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study was designed to evaluate the safety and pharmacokinetic interaction between THP-00101 and THP-00102 in healthy adult volunteers.

Conditions

  • Hypertension
  • Diabetes Mellitus, Type 2

Interventions

  • THP-00101 (Dapagliflozin) 10mgDrug

    Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B

  • THP-00102 (Telmisartan) 80mgDrug

    Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics - AUCτ,ssTime frame: Day 1 to Day 11
  2. Pharmacokinetics - Cmax,ssTime frame: Day 1 to Day 11
  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Day 1 to Day 17

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H Plus Yangji Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.